Why the study?
Does combined aspirin and dipyridamole reduce platelet deposition and thrombus formation on hemodialysis membranes in long-term dialysis patients?
Does combined aspirin and dipyridamole reduce platelet deposition and thrombus formation on hemodialysis membranes in long-term dialysis patients?
Combined aspirin and dipyridamole therapy provides a dose-dependent reduction in platelet consumption and fibrin activation on Cuprophan membranes during hemodialysis.
Answers are grounded in this paper and cite their sources.
High-dose aspirin-dipyridamole warrants consideration to reduce dialyzer platelet loss; extends antiplatelet evidence to Cuprophan membrane interactions in long-term hemodialysis.
A double-blind crossover study comparing low-dose aspirin (ASA) and dipyridamole (DPM) (100 mg ASA + 75 mg DPM, t.d.s.), high-dose ASA and DPM (300 mg ASA + 75 mg DPM, t.d.s.), and placebo on platelet deposition and thrombus formation on hemodialysis membranes was undertaken in 17 long-term dialysis patients. The high-dose combination significantly reduced the fall in platelet count during dialysis and also significantly increased postdialysis heparin concentrations. Scanning electron microscopy of the Cuprophan membranes showed a reduction in platelet deposition and fibrin formation during both treatment schedules, but this was most marked with the high-dose combination. The results of this study indicate that there is a graded response to combined ASA-DPM treatment and that this can significantly reduce platelet consumption and contact activation of fibrin during hemodialysis with Cuprophan membranes.
No takes yet. Share an insight, caveat, or question.
Salter et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: